CD22 and systemic mastocytosis: Thus, we performed such an analysis for the first time, by investigating the expression of a broad panel of markers (CD22, CD25, CD30, CD33, CD123, and FcεRI) that have been reported to be expressed on clonal BMMC from SM patients.